Can Computed Tomography Perfusion Predict Treatment Response After Prostate Artery Embolization: A Feasibility Study.

Area of Science:

• Interventional Radiology
• Urology
• Medical Imaging

Background:

• Prostate artery embolization (PAE) is a developing treatment for benign prostatic hyperplasia (BPH).
• Effective patient selection is crucial for new therapies like PAE.
• Currently, no validated prognostic tool exists for predicting PAE outcomes.

Purpose of the Study:

• To investigate the relationship between baseline prostatic blood flow (PBF), measured by computed tomography perfusion, and the clinical response to PAE.
• To determine if PBF can serve as a predictor for PAE treatment success.

Main Methods:

• A post hoc analysis of data from two prospective studies involving sixteen patients undergoing PAE for BPH or prostate cancer.
• Measurements included prostate-specific antigen (PSA) levels before and 24 hours after embolization.
• Computed tomography (CT) perfusion was used to estimate baseline PBF.

Main Results:

• Prostate volume demonstrated a strong correlation with treatment response to PAE.
• Higher volumes of embolic material injected were associated with greater treatment response.
• Baseline prostatic blood flow (PBF) was not found to be associated with changes in PSA levels and did not aid in patient selection.

Conclusions:

• Prostate volume is a significant factor in predicting treatment response to PAE for BPH.
• Prostatic blood flow (PBF) measurements using CT perfusion do not currently offer additional predictive value for PAE outcomes.
• Further research may be needed to identify optimal patient selection criteria for PAE.